Treatment with biologic DMARDs vs standard therapy improved clinical response rates and flare outcomes among patients with polyarticular JIA.

The FDA expanded the approval of Cablivi to include pediatric patients 12 years and older with acquired thrombotic thrombocytopenic purpura.

Atsena Therapeutics, a clinical-stage gene therapy company focused on using the life-changing power of genetic medicine to reverse or prevent blindness, today announced that dosing is complete in ...

The Trump administration overhauled the US pediatric vaccine schedule on January 5, 2026, upending years of scientifically ...

The treatment for acquired thrombotic thrombocytopenic purpura, a rare blood disorder that causes blood clots in the small ...

Weight-loss experts reveal their major predictions for 2026, from advanced GLP-1 treatments to AI-driven personalized therapy ...

In 2023, the FDA and CDC's Advisory Committee on Immunization Practices (ACIP) voted in favor of recommending the monoclonal ...

CorMedix Therapeutics is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases.

LYNX-3, the second pivotal Phase 3 trial in keratorefractive participants with visual disturbances under mesopic, low-contrast conditions, is ongoing with topline results expected in the first half of ...

Q4 2025 Unaudited Net Revenue of Approximately $127 million ‒‒ FY 2025 Unaudited Pro Forma Net Revenue of Approximately $400 million ‒‒ Expects ...

Changes to US childhood vaccine recommendations by the Department of Health and Human Services. Experts express concern amid ...